EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of TriGUARD 3 on cerebral protection in Chinese patients undergoing transcatheter aortic valve replacement

Yanbin Li, Bin Wang, Shichen Zhou, Yujie Zhou, Mao Chen, Jianfang Luo, Jianan Wang, Jun Jin, Xiaoping Peng, Jianzeng Dong, Zening Jin, Yongjun Wang und 2 weitere

Frontiers in Cardiovascular Medicine · 18.03.2026 · 13

DOI: 10.3389/fcvm.2026.1694878 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 18.03.2026. Verfasst von Yanbin Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Frigid Zone Cardiovascular Diseases, Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Li…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In China, evidence regarding cerebral embolic protection device (CEPD) use during transcatheter aortic valve replacement (TAVR) for severe aortic stenosis treatment is limited. This study evaluated the TriGUARD 3 (TG3) CEPD performance in patients undergoing TAVR.

Methods

Data from two studies were pooled: the CEPD group was derived from a multicenter TG3 trial in China, whereas the control group was obtained from a single-center registry. All participants underwent transfemoral TAVR and completed pre- and postoperative diffusion-weighted magnetic resonance imaging (DW-MRI). The primary outcome was total cerebral ischemic lesion volume on DW-MRI.

Results

No significant difference was observed between groups in total lesion volume {CEPD [ n = 62] vs. control [ n = 56]; 256.53 [interquartile range (IQR), 44.12–667.99] vs. 271.88 [IQR, 96.10–650.87]; p = 0.456}. Median regression analysis in the overall cohort showed no significant association between CEPD use and total lesion volume ( p = 0.181). Nonetheless, among patients with bicuspid aortic valve (BAV) stenosis, the CEPD group demonstrated significantly lower total lesion volume [165.43 (IQR, 32.96–311.13) vs. 309.38 (IQR, 96.10–788.49); p = 0.025], average lesion volume [61.3 (IQR, 23.44–89.65) vs. 93.75 (IQR, 51.73–137.07); p = 0.019], and maximum single-lesion volume [89.65 (IQR, 28.13–174.02) vs. 164.14 (IQR, 75.00–365.08); p = 0.019]. Median regression revealed that CEPD use was significantly associated with reductions in total, average, and maximum single-lesion volumes (median differences: −406.1, −82.2, and −137.6; all p < 0.05), independent of age, sex, hypertension, diabetes, valve type, and pre-dilatation.

Conclusion

In patients with severe aortic stenosis undergoing transfemoral TAVR, TG3 CEPD did not significantly reduce the total lesion volume on DW-MRI. In the BAV subgroup, an association was observed between device use and reductions in total, average, and maximum single-lesion volumes. This exploratory finding is hypothesis-generating and should be further elucidated in larger randomized studies.

Schlagwörter

Stichwörter der Autor:innen

bicuspid stenosiscerebral ischemiadiffusion-weighted imagingembolic protectionneuroprotectiontranscatheter valve replacement

Autor:innen und Institutionen

  • The State Key Laboratory of Frigid Zone Cardiovascular Diseases, Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
  • Department of Cardiology, Benxi Central Hospital, Benxi, Liaoning, China.
  • Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Cardiology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China.
  • Department of Cardiology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Zitieren

APA

Li, Y., Wang, B., Zhou, S., Zhou, Y., Chen, M., Luo, J., Wang, J., Jin, J., Peng, X., Dong, J., Jin, Z., Wang, Y., Xu, K., & Han, Y. (2026). Impact of TriGUARD 3 on cerebral protection in Chinese patients undergoing transcatheter aortic valve replacement. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1694878

Vancouver

Li Y, Wang B, Zhou S, Zhou Y, Chen M, Luo J, et al. Impact of TriGUARD 3 on cerebral protection in Chinese patients undergoing transcatheter aortic valve replacement. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1694878

BibTeX
@article{Li2026,
  author = {Li, Yanbin and Wang, Bin and Zhou, Shichen and Zhou, Yujie and Chen, Mao and Luo, Jianfang and Wang, Jianan and Jin, Jun and Peng, Xiaoping and Dong, Jianzeng and Jin, Zening and Wang, Yongjun and Xu, Kai and Han, Yaling},
  title = {Impact of TriGUARD 3 on cerebral protection in Chinese patients undergoing transcatheter aortic valve replacement},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1694878}
}
Kostenlos starten →